natgillin/translations-raw huggingface dataset:
All patients must have their CPK levels measured at the beginning of their treatment and at regular intervals, particularly if they have any known risk factors for muscle damage.
Vsem bolnikom je treba na začetku zdravljenja in v rednih presledkih izmeriti raven krvnega encima CPK, še zlasti, če pri njih obstajajo znani dejavniki tveganja za poškodbe mišic.
All patients must receive adequate supplemental calcium and vitamin D. Anaphylactic reaction/shock
Vsi bolniki morajo prejemati ustrezne dodatke kalcija in vitamina D. Anafilaktična reakcija/šok
All patients must receive corticosteroids e.g.
Vsi bolniki morajo prejeti kortikosteroid, tj.
All patients N = 74
Vsi bolniki N = 74
All patients Newly diagnosed Relapsing
Vsi bolniki Novoodkriti Ponovitev
All patients other than those with severe hepatic or renal impairment (see below) should initiate treatment at the recommended 24 mg dose, following which the dose should be further adjusted on the basis of individual tolerability.
Vsi bolniki razen tistih, ki imajo hudo okvaro jeter ali ledvic (glejte v nadaljevanju), naj začnejo z zdravljenjem s priporočenim odmerkom 24 mg, nato pa naj se odmerek še nadalje prilagaja na podlagi prenašanja vsakega bolnika posebej.
All patients received a 2-week standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by Week 15.
Vsi bolniki so ob začetku študije prejeli 2- tedenski standardizirani odmerek prednizolona 60 mg/dan, čemur je sledil obvezen program postopnega zmanjševanja, s popolno ukinitvijo kortikosteroidov do 15. tedna.
All patients received a total dose of cisplatin of 480 mg/m2 as part of their induction (neoadjuvant) and/or maintenance (adjuvant) chemotherapy regimen.
Vsi bolniki so prejeli skupni odmerek cisplatina 480 mg/m2 v sklopu njihovega začetnega (neoadjuvantnega) in/ali vzdrževalnega (adjuvantnega) režima kemoterapije.
All patients received adequate supplementation with vitamin D and calcium in the post-menopausal osteoporosis trial, the prevention of clinical fractures after hip fracture trial, and the Paget’s disease trials (see also section 4.2).
V preskušanju zdravljenja postmenopavzalne osteoporoze, v preskušanju preventive kliničnih zlomov po zlomu kolka in v preskušanjih zdravljenja Pagetove bolezni so vsi bolniki prejemali ustrezne dodatke vitamina D in kalcija (glejte tudi poglavje 4.2).
All patients received background non-biologic DMARD(s).
Vsi bolniki so prejeli osnovno zdravljenje z enim ali večimi nebiološkimi imunomodulirajočimi antirevmatičnimi zdravili.
All patients received Cosentyx 150 mg or 300 mg doses at Weeks 0, 1, 2, 3, 4, 8 and 12 and then were randomised to receive either a maintenance regimen of the same dose every month starting at Week 12 or a “retreatment as needed” regimen of the same dose.
Vsi bolniki so prejemali zdravilo Cosentyx v odmerku 150 mg oziroma 300 mg v tednih 0, 1, 2, 3, 4, 8 in 12, nato pa so jih randomizirali tako, da so zdravilo prejemali bodisi po vzdrževalnem režimu v enakem odmerku enkrat na mesec z začetkom v 12. tednu ali pa po režimu "ponovitve zdravljenja po potrebi" z enakimi odmerki.
All patients received doses of 150 mg twice daily of dabigatran etexilate.
Vsi bolniki so jemali dabigatran eteksilata v odmerkih po 150 mg dvakrat na dan.
All patients received doses of 150 mg twice daily of dabigatran etexilate.
Vsi bolniki so jemali odmerke dabigatran eteksilata po 150 mg dvakrat na dan.
All patients received folate 1 mg bid.
Vsi so dobivali 1 mg folata dvakrat na dan.
All patients received IV tigecycline for a minimum of 3 consecutive days to a maximum of 14 consecutive days, with the option to be switched to an oral antibiotic on or after day 4.
Vsi bolniki so prejemali tigeciklin i.v. vsaj 3 zaporedne dni do največ 14 zaporednih dni z možnostjo prehoda na peroralni antibiotik 4. dan ali pozneje.
All patients received prophylactic anticoagulation (low molecular weight heparin, warfarin, heparin, low-dose aspirin) during the study.
Vsi bolniki so med študijo prejemali profilaktično antikoagulacijo terapijo (heparin majhne molekulske mase, varfarin, heparin, acetilsalicilno kislino v majhnem odmerku).
All patients received prophylactic anticoagulation (low molecular weight heparin, warfarin, heparin, low-dose aspirin) during the study.
Vsi bolniki so med študijo prejemali profilaktično antikoagulacijo terapijo (heparin majhne molekulske mase, varfarin, heparin, acetilsalicino kislino v majhnem odmerku).
All patients received ribavirin at a fixed dose of 800 mg/day.
Vsi bolniki so prejeli fiksni, 800 mg odmerek ribavirina na dan.
All patients received routine standard of care and were randomised to either placebo or eptifibatide (2 bolus doses of 180 microgram/kg and a continuous infusion until discharge from hospital or a maximum of 18-24 hours).
Vsi bolniki so bili deležni rutinske zdravstvene oskrbe in so bili naključno razporejeni bodisi v skupino, ki bo prejemala placebo, ali v skupino, ki bo prejemala eptifibatid (2 bolusna odmerka po 180 mikrogramov/kg in kontinuirana infuzija do odpusta iz bolnišnice ali največ 18 do 24 ur).
All patients received Soliris and the study measured the number of red blood cell transfusions needed during the 12 weeks of treatment.
Vsi bolniki so prejeli zdravilo Soliris, v študiji pa so merili, koliko transfuzij rdečih krvnih celic je bilo potrebnih v 12 tednih zdravljenja.
All patients received standard of care analgesia during treatment.
Vsi bolniki so bili med zdravljenjem deležni standardne analgezije.
All patients received TAGRISSO at a dose of 80 mg once daily.
Vsi bolniki so prejemali zdravilo TAGRISSO v odmerku 80 mg enkrat na dan.
All patients received tenofovir + emtricitabine as background therapy.
Vsi bolniki so prejemali osnovno zdravljenje s tenofovirjem + emtricitabinom.
All patients receiving DepoCyte should be treated concurrently with dexamethasone to mitigate the symptoms of arachnoiditis.
Vsi bolniki, ki prejemajo zdravilo DepoCyte, morajo sočasno prejeti tudi deksametazon za ublažitev simptomov arahnitisa.
All patients receiving Lojuxta in addition to a statin should be advised of the potential increased risk of myopathy and told to report promptly any unexplained muscle pain, tenderness, or weakness.
Vsem bolnikom, ki sočasno prejemajo zdravilo Lojuxta ter statin, je treba svetovati glede morebitnega povečanega tveganja za miopatijo in jim naročiti, naj takoj poročajo o kakršni koli nepojasnjeni mišični bolečini, občutljivosti ali šibkosti.
All patients receiving Myocet should also routinely undergo ECG monitoring.
Vse bolnice, ki prejemajo zdravilo Myocet, morate rutinsko pregledovati tudi z EKG.
All patients recovered without sequelae.
Vsi bolniki so okrevali brez posledic.
All patients remained susceptible to tenofovir.
Vsi bolniki so bili še naprej občutljivi na tenofovir.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Humira.
Vsem bolnikom je treba naročiti, naj nemudoma poiščejo zdravniško pomoč, če se jim med uporabo zdravila Humira pojavijo znaki ali simptomi krvnih diskrazij (npr. trajno zvišana telesna temperatura, podplutbe, krvavitve, bledica).
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor).
Kljub temu vsem bolnikom svetujte, naj nemudoma poiščejo zdravniško pomoč, če se pri njih pojavijo znaki in simptomi, ki kažejo na pojav krvne diskrazije (npr. trdovratno zvišana telesna temperatura, podplutbe, krvavitve in bledica).
All patients should be advised to seek medical attention promptly at the first sign of infection (eg, cough, fever, etc) thereby allowing for early management to reduce severity.
Vsem bolnikom morate svetovati, naj pri prvem znaku okužbe (npr. kašelj, zvišana telesna temperatura, itn.) takoj poiščejo zdravniško pomoč, s čimer bodo omogočili zgodnje zdravljenje in s tem manjšo resnost okužbe.
All patients should be assessed at least once every two years.
Vse bolnike je treba pregledati vsaj vsaki dve leti.
All patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling or non-healing of sores or discharge during treatment with Prolia.
Vsem bolnikom je treba naročiti, da morajo vzdrževati dobro ustno higieno, redno opravljati zobozdravniške preglede in med zdravljenjem z zdravilom Prolia nemudoma obvestiti zdravnika, če se pojavi kakršen koli simptom v ustih, na primer majanje zob, bolečina ali oteklina, rana, ki se ne celi, ali izcedek.
All patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with XGEVA.
Vsem bolnikom je treba naročiti, da morajo med zdravljenjem z zdravilom XGEVA vzdrževati dobro ustno higieno, redno opravljati zobozdravniške preglede in nemudoma obvestiti zdravnika, če se pojavi kakršen koli simptom v ustih, na primer majanje zob, bolečina, oteklina, rana, ki se ne celi, ali izcedek.
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with zoledronic acid.
Vsem bolnikom je treba naročiti, naj v času zdravljenja z zdravilom zoledronsko kislino skrbijo za dobro ustno higieno in redno hodijo na preglede k zobozdravniku, v primeru simptomov v ustni votlini, kot so majavost zob, bolečine, otekline ali neceljenje ran ali vnetje, pa naj takoj obvestijo zdravnika.
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with zoledronic acid.
Vsem bolnikom je treba naročiti, naj v času zdravljenja z zoledronsko kislino skrbijo za dobro ustno higieno in redno hodijo na preglede k zobozdravniku, v primeru simptomov v ustni votlini, kot so majavost zob, bolečine, otekline ali neceljenje ran ali vnetje, pa naj takoj obvestijo zdravnika.
All patients should be formally reviewed after approximately six weeks of Bronchitol treatment to assess for signs and symptoms suggestive of drug induced bronchospasm.
Vse bolnike je treba pregledati po približno šestih tednih zdravljenja z zdravilom Bronchitol za znake in simptome, ki kažejo na bronhospazem, induciran z zdravilom.
All patients should be fully informed that cardiovascular risks should be monitored on a regular basis generally every 6-12 months.
Vsi bolniki morajo biti v celoti obveščeni, o tem, da je potrebno tveganje za srčno-žilne dogodke spremljati v rednih časovnih presledkih, vsakih 6 do 12 mesecev.
All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Inflectra treatment.
Vsem bolnikom morate naročiti, naj pridejo k zdravniku, če se v času zdravljenja z zdravilom Inflectra ali po njem pojavijo znaki ali simptomi, ki kažejo na tuberkulozo (npr. trdovraten kašelj, hujšanje ali nekoliko zvišana telesna temperatura).
All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Remsima treatment.
Vsem bolnikom morate naročiti, naj pridejo k zdravniku, če se v času zdravljenja z zdravilom Remsima ali po njem pojavijo znaki ali simptomi, ki kažejo na tuberkulozo (npr. trdovraten kašelj, hujšanje ali nekoliko zvišana telesna temperatura).
All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Simponi treatment.
Vsem bolnikom naročite, naj poiščejo zdravniško pomoč, če se med ali po zdravljenju z zdravilom Simponi pojavijo znaki/simptomi, ki kažejo na tuberkulozo (npr. trdovraten kašelj, hiranje/hujšanje, malo zvišana telesna temperatura).
All patients should be instructed to avoid chronic or acute excessive alcohol use while taking eluxadoline.
Vse bolnike je treba opozoriti, da med jemanjem eluksadolina ne smejo kronično ali akutno čezmerno uživati alkohola.
All patients should be instructed to seek medical advice if signs or symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, subfebrile temperature) appear during Ilaris therapy.
Vsem bolnikom je treba naročiti, naj obiščejo zdravnika, če v času zdravljenja z zdravilom Ilaris opazijo znake ali simptome, ki bi kazali na tuberkulozo (na primer trdovraten kašelj, zmanjševanje telesne mase, subfebrilne temperature).
All patients should be monitored and informed about the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, weight-loss, hypotension, hyponatraemia, hyperkalaemia and/or hypoglycaemia).
Vse bolnike je treba spremljati in jih obvestiti o znakih ter simptomih, povezanih s hipokorticizmom (npr. šibkost, utrujenost, anoreksija, navzea, bruhanje, izguba telesne mase, hipotenzija, hiponatriemija, hiperkaliemija in/ali hipoglikemija).
All patients should be provided with training by the prescribing Health Care Professional on how to use Aerivio Spiromax.
Vse bolnike mora o uporabi inhalatorja Spiromax za zdravilo Airexar podučiti zdravstveni delavec.
All patients should be routinely evaluated for hypertension and treated as needed.
Vse bolnike je treba redno ocenjevati glede hipertenzije in jih zdraviti, kot je potrebno.
All patients should be started on dexamethasone 4 mg twice daily either orally or intravenously for 5 days beginning on the day of DepoCyte injection.
Vsi bolniki morajo na dan injiciranja zdravila DepoCyte začeti jemati 4 mg deksametazona dvakrat dnevno bodisi peroralno bodisi intravensko, in z jemanjem nadaljevati 5 dni.
All patients should be started on dexamethasone 4 mg twice daily either orally or intravenously for 5 days beginning on the day of injection of DepoCyte.
Na dan injiciranja zdravila DepoCyte morajo vsi bolniki začeti prejemati po 4-mg deksametazona bodisi peroralno bodisi intravensko, in sicer 5 dni dvakrat dnevno.
All patients should continue their diet with an adequate distribution of carbohydrate intake during the day.
Vsi bolniki morajo nadaljevati dieto z ustrezno porazdelitvijo vnosa ogljikovih hidratov čez dan.
All patients should continue their diet with regular distribution of carbohydrate intake during the day.
Vsi bolniki morajo nadaljevati z dieto, obroki z ogljikovimi hidrati morajo biti razdeljeni skozi ves dan.
All patients should have liver function tests to determine whether they have hepatic impairment before starting and during pazopanib therapy (see section 4.4).
Pri vseh bolnikih je treba opraviti teste jetrne funkcije, da bi ugotovili morebitno okvaro jeter; opraviti jih je treba pred začetkom zdravljenja s pazopanibom in med zdravljenjem z njim (glejte poglavje 4.4).
All patients should receive ASA immediately after the diagnosis of acute STEMI as long as there will be no contraindications (the medicinal product is administered at a dose of 75 mg to 325 mg once daily).
Vsi bolniki morajo ASK prejeti takoj, ko je pri njih diagnosticiran STEMI, če pri njih ni kontraindicirana (zdravilo je treba dati v odmerku od 75 mg do 325 mg enkrat na dan).
All patients switching from enzyme replacement should be regularly monitored for disease progression.
Pri vseh bolnikih, ki preidejo na zdravilo Cerdelga z encimskega nadomestnega zdravljenja, je treba redno spremljati napredovanje bolezni.
All patients treated with Corbilta should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour.
Vse bolnike, ki se zdravijo z zdravilom Corbilta, je treba skrbno spremljati, če bi prišlo do psihičnih sprememb, depresije s samomorilnimi nagnjenji ter drugih resnih oblik antisocialnega vedenja.
All patients treated with Levodopa/Carbidopa/Entacapone Orion should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour.
Vse bolnike, ki se zdravijo z zdravilom Levodopa/Carbidopa/Entacapone Orion, je treba skrbno spremljati, če bi prišlo do psihičnih sprememb, depresije s samomorilnimi nagnjenji ter drugih resnih oblik antisocialnega vedenja.
All patients treated with MabThera for rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis must be given the patient alert card with each infusion.
Vsem bolnikom, ki se z zdravilom MabThera zdravijo za revmatoidni artritis, granulomatozo s poliangiitisom in mikroskopski poliangiitis, je treba ob vsaki infuziji dati opozorilno izkaznico (glejte Dodatek IIIA – Označevanje).
All patients treated with RoActemra should be given the Patient Alert Card.
Vsi bolniki, ki se zdravijo z zdravilom RoActemra, morajo dobiti opozorilno izkaznico.
All patients treated with Stalevo should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour.
Vse bolnike, ki se zdravijo z zdravilom Stalevo, je treba skrbno spremljati, če bi prišlo do psihičnih sprememb, depresije s samomorilnimi nagnjenji ter drugih resnih oblik antisocialnega vedenja.
All patients treated with Zydelig should be given preventive medication against the lung infection Pneumocystis jirovecii pneumonia during treatment, and this should be continued for up to 6 months after treatment with Zydelig has stopped.
Vsi bolniki, ki se zdravijo z zdravilom Zydelig, morajo ves čas zdravljenja prejemati preventivno zdravilo proti okužbi s pljučnico Pneumocystis jirovecii, kar je treba nadaljevati do največ šest mesecev po koncu zdravljenja z zdravilom Zydelig.
All patients were also taking concomitant opioids, such as sustained-release morphine or transdermal fentanyl, for their persistent pain.
Vsi bolniki so zaradi stalnih bolečin sočasno jemali tudi opioide, npr. morfij s podaljšanim sproščanjem ali transdermalni fentanil.
All patients were also taking other anti- epileptic medicines.
Vsi bolniki so prejemali tudi druga zdravila proti epilepsiji.
All patients were also treated with ASA for at least 30 days.
Vsi bolniki so hkrati vsaj 30 dni prejemali tudi acetilsalicilno kislino (ASK).
All patients were diagnosed with Stage IIIB or IV NSCLC and had received prior platinum- based chemotherapy.
Vsi bolniki so imeli diagnozo nedrobnoceličnega pljučnega karcinoma IIIB ali IV. stopnje in so predhodno prejemali kemoterapijo na osnovi platine.
All patients were freely ambulatory and all but one patient did not require any form of ventilator support (1 patient required nocturnal non- invasive ventilation).
Vsi bolniki so bili zdravljeni ambulantno in razen enega, nihče ni potreboval kakršnekoli oblike respiracijske pomoči (1 bolnik je potreboval nočno ne-invazivno predihavanje).
All patients were non-cirrhotic in these two studies.
Vsi bolniki v teh dveh študijah so bili brez ciroze.
All patients were required to have a smoking history of at least 10 pack years; a post-salbutamol FEV1/FVC ratio less than or equal to 0.70; post-salbutamol FEV1 less than or equal to 70% predicted and have a Modified Medical Research Council (mMRC) dyspnea score 2 (scale 0-4) at screening.
Vsi bolniki so morali imeti anamnezo kajenja vsaj 10 škatlic-let, razmerje FEV1/FVC po salbutamolu manj ali enako 0,70, FEV1 po salbutamolu manj ali enako 70 % predvidenega ter oceno mMRC (Modified Medical Research Council)  2 (lestvica 0-4) o presejanju.
All patients who are prescribed Cerdelga will be provided with a patient alert card.
Vsi bolniki, ki jim predpišejo zdravilo Cerdelga, bodo prejeli opozorilno kartico.
All patients who did not have progressive disease were to receive CRT as per protocol (PF/CRT).
Vsi bolniki, ki niso imeli napredujoče bolezni, so dobili kemoradioterapijo po protokolu (PF/KRT).
All patients who receive PhotoBarr will be photosensitive (sensitive to light) and must observe precautions to avoid direct sunlight and bright indoor light (see above ‘How to prevent a photosensitivity reaction’).
Vsi bolniki, ki dobivajo PhotoBarr, so fotosenzitivni (občutljivi na svetlobo) in morajo upoštevati posebna opozorila, da se izognejo neposredni sončni svetlobi in močni notranji svetlobi (glejte zgoraj 'Kako preprečimo fotosenzitivne reakcije').
All patients who receive PhotoBarr will be photosensitive and must observe precautions to avoid exposure of skin and eyes to direct sunlight or bright indoor light (from examination lamps, including dental lamps, operating room lamps, unshaded light bulbs at close proximity, neon lights, etc.) for at least 90 days after treatment as some patients may remain photosensitive for up to 90 days or more.
Vsi bolniki, ki dobivajo PhotoBarr, so občutljivi na svetlobo in morajo upoštevati posebna opozorila, da se izognejo izpostavljenosti kože in oči neposredni sončni svetlobi ali močni notranji svetlobi (svetilke za opazovanje, vključno z zobozdravstvenimi svetilkami, lučmi v operacijskih dvoranah, nezasenčenimi žarnicami v neposredni bližini, neonskimi lučmi itd.), najmanj 90 dni po zdravljenju, ker lahko nekateri bolniki ostanejo občutljivi na svetlobo še do 90 dni ali več.
All patients who tested positive for binding antibodies also tested positive for neutralising anti-blinatumomab antibodies.
Vsi bolniki, ki so imeli pozitiven izvid vezavnih protiteles, so imeli tudi pozitiven izvid nevtralizacijskih protiteles proti blinatumomabu.
All patients who were found to carry oseltamivir-resistant virus did so transiently, cleared the virus normally and showed no clinical deterioration.
Vsi bolniki pri katerih so odkrili virusne seve, odporne na oseltamivir, so te seve nosili prehodno, viruse so normalno preboleli in niso kazali kliničnega poslabšanja.
All patients who were found to carry oseltamivir-resistant virus did so transiently, cleared the virus normally and showed no clinical deterioration.
Vsi bolniki, pri katerih so odkrili virusne seve, odporne na oseltamivir, so te seve nosili prehodno, viruse so normalno preboleli in niso kazali kliničnega poslabšanja.
All patients will show a dark red colouration of the urine quite marked during the three days following administration.
Pri vseh bolnikih se bo v prvih treh dneh po uporabi pojavilo znatno temno rdeče obarvanje urina.
all patients with acquired haemophilia and who are treated with Obizur, the MAH must
pridobljeno hemofilijo in ki se zdravijo z zdravilom OBIZUR, v skladu s potrjenim
All patients with impaired renal function should consider a dietary recommendation to reduce sodium intake (see section 4.4).
Pri vseh bolnikih z ledvično okvaro je treba upoštevati priporočilo za zmanjšanje vnosa natrija s hrano (glejte poglavje 4.4).
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of non- melanoma skin cancer prior to and during treatment with Humira.
Pred zdravljenjem z zdravilom Humira in med zdravljenjem z njim je treba za nemelanomskega kožnega raka pregledati vse bolnike, še zlasti pa bolnike z anamnezo intenzivne imunosupresivne terapije in bolnike s psoriazo, ki so kdaj prejemali PUVA.
All patients, especially children, should be up-to-date with all their vaccinations before they start treatment with RoActemra.
Vsi bolniki, še posebno otroci, morajo pred začetkom zdravljenja z zdravilom RoActemra prejeti vsa cepiva.
All Patients, RD=F Analysis2
Vsi bolniki, RD=F analiza2
All Patientsa
Vsi bolnikia
All Patientsa N=540
Vsi bolnikia N = 540
All patientsd
Vsi bolnikid
All patients†
Vsi bolniki
All patients† 62 (57, 67) 33 (27, 39) 57 (52, 62) 26 (21, 32)
Vsi bolniki† 62 (57, 67) 33 (27, 39) 57 (52, 62) 26 (21, 32)